Diffuse large B-cell lymphoma (DLBCL), the most common hematologic cancer in the US, is characterized by marked molecular and clinical heterogeneity. African American (AA) and Hispanic patients experience inferior outcomes due to biologic factors that remain poorly understood, in addition to well-described socioecono...
J. Koff, Jonathon B. Cohen, Lee A. D. Cooper et al.· Cancer Epidemiology, Biomark...· 0 citations
A 2025 National Academies' report, The Science and Practice of Team Science, identified critical gaps in leadership development and highlighted evidence-based best practices and infrastructure needs to enhance team science. This brief perspective addresses team science approaches needed to overcome the complexities of...
Christopher R. Flowers, Shi-Ne Chang, HwaYoung Lee et al.· Clinical Cancer Research· 0 citations
The clinical utility and acceptable TAT of a comprehensive WES and RNA-seq assay for LBCL managed in routine clinical practice are demonstrated and support the real-world feasibility of using integrated WES and RNA-seq to define molecular subgroups, guide clinical decision-making at the time of a new line of therapy, a...
Dai Chihara, Kumudha Balakrishnan, G. Masand et al.· Blood Advances· 0 citations
This White Paper written by the Global Lymphoma Registry Alliance (LyRA) discusses the importance and value of lymphoma registries for different stakeholders as well as benefits of forming a global alliance of the registry network.
Eliza A. Hawkes, E. Chung, M. Bishton et al.· Haematologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
